Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic.

• Tác giả: Thomas B Arnold, John Logan Black, Mauricio De Castro, Nate Ehat, Keiko Fox, Mark Haigney, Lydia D Hellwig, Andrew Heroy, Sachi Kalra, Joya Libbus, Ann M Moyer, Austin Pagani, Lucas Poon, David Saunders, Steven E Scherer, Clesson Turner
• Ngôn ngữ: eng
• Ký hiệu phân loại: 633.72 *Tea
• Thông tin xuất bản: England : Pharmacogenomics , 2025
• Bộ sưu tập: NCBI
• ID: 238871

Tóm tắt

INTRODUCTION: Pharmacogenetic (PGx) screening is intended to optimize drug efficacy and reduce adverse drug reactions. Current screening options include genotyping assays for preselected PGx variants and broader next-generation sequencing panels (NGS). Few studies have directly compared preemptive PGx screening methods. MATERIALS AND METHODS: The two PGx methods were compared in a cross-sectional study of adult Military Health System (MHS) clinic beneficiaries. Participants had initial targeted CYP2C19/CYP2D6 genotyping at a Military Health System Laboratory. Genotyping was followed by multi-gene NGS testing. Current prescriptions were recorded and potential drug-drug interactions screened to evaluate prescribing risk. RESULTS: All participants (100%) had at least one clinically actionable NGS panel result compared to 81% with targeted CYP2C19/CYP2D6 genotyping. Participants ( CONCLUSIONS: Preemptive multi-gene NGS detected more clinically actionable PGx results than targeted